A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Phase 1/2 Unknown 115 enrolled Qilu Pharmaceutical Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

Evaluation	Drug	Modality	Dose	Route
Subject	QLS31905	Unknown	—	Intravenous
Background	Capecitabine	Small molecule	1000 mg/m2	Oral
Background	Cisplatin	Other / unclassified	25 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous